Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pepinemab - Vaccinex

Next Previous
X
Search
Drug Profile

Pepinemab - Vaccinex

Alternative Names: moAb VX15/2503; VX 15; VX 15/2503

Latest Information Update: 20 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaccinex
  • Developer Bristol-Myers Squibb; Children's Oncology Group; Emory University; Merck KGaA; National Cancer Institute (USA); Teva Pharmaceutical Industries; UCLAs Jonsson Comprehensive Cancer Center; Vaccinex
  • Class Antibodies; Antidementias; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD100 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Huntington's disease

Highest Development Phases

  • Phase II Huntington's disease
  • Phase I/II Adenocarcinoma; Alzheimer's disease; Non-small cell lung cancer; Osteosarcoma; Solid tumours; Squamous cell cancer
  • Phase I HER2 positive breast cancer; Malignant melanoma
  • No development reported Colorectal cancer; Multiple sclerosis; Pancreatic cancer

Most Recent Events

  • 20 Aug 2024 Pepinemab - Vaccinex is available for licensing as of 14 Aug 2024
  • 31 Jul 2024 Efficacy and adverse events data from the phase Ib/IIa SIGNAL-AD trial in Alzheimer’s Disease released by Vaccinex
  • 05 Jun 2024 Vaccinex completes a phase I/IIa SIGNAL-AD trial for Alzheimer's disease in USA (NCT04381468)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top